Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

Vaccine

Volumn 20, Issue 7-8, 2002, Pages 1058-1067

  Konishi, Eiji ^a   Fujii, Atsuko ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Dengue; Subunit vaccine; Subviral particles

Indexed keywords

DENGUE VACCINE; ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN PURIFICATION; ARTICLE; CELL LINE; CONTROLLED STUDY; DENGUE VIRUS; DRUG SCREENING; FEMALE; GENETIC TRANSFECTION; IMMUNIZATION; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; SOMATOSTATIN CELL; VERO CELL; VIRUS EXPRESSION; VIRUS STRAIN;

ANIMALS; BASE SEQUENCE; CHO CELLS; CRICETINAE; DENGUE VIRUS; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MOLECULAR SEQUENCE DATA; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0037081397     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00446-7     Document Type: Article

References (63)

1. Dengue: The risk to developed and developing countries
2. Dengue and dengue hemorrhagic fever
3. A live attenuated dengue type 1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans
4. Testing of a dengue type 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers
5. Live attenuated tetravalent dengue vaccine
6. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus non-structural protein NS1 protects against lethal dengue virus encephalitis
7. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice
8. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge
9. Recombinant vaccinia viruses co-expressing dengue type 1 glycoproteins prM and E induce neutralizing antibodies in mice
10. Evaluation of molecular strategies to develop a live dengue vaccine
11. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine
12. Recombinant chimeric yellow fever - Dengue type 2 virus is immunogenic and protective in non-human primates
13. Protective efficacy of a dengue type 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses
14. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein
15. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys
16. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice
17. Analysis of a recombinant dengue type 2 virus-dengue type 3 virus hybrid envelope protein expressed in a secretory baculovirus system
18. Affinity-purified dengue type 2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice
19. Expression of the dengue virus structural proteins in Pichia pastoris leads to the generation of virus-like particles
20. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue type 2 virus infection in mice
21. Purified dengue type 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice
22. Over a decade of experience with a yeast recombinant hepatitis B vaccine
23. Flavivirus genome organization, expression, and replication
24. Monoclonal antibodies against dengue type 2 virus E-glycoprotein protect mice against lethal dengue infection
25. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection
26. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue type 2 virus
27. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies
28. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein
29. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection
30. Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus
31. Mice immunized with a subviral particle containing the Japanese encephalitis virus pr/M and E proteins are protected from lethal JEV infection
32. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis
33. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form
34. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a non-infectious recombinant antigen that can be used in enzyme-linked immunosorbent assays
35. Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles
36. Proteolytic activation of tick-borne encephalitis virus by furin
37. Isolation of a Singh's Aedes albopictus cell clone sensitive to dengue and chikungunya viruses
38. A general method of in vitro preparation and specific mutagenesis of DNA fragments: Study of protein and DNA interactions
39. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene
40. Identification of distinct antigenic determinants on dengue type 2 virus using monoclonal antibodies
41. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence
42. Production and characterization of arbovirus antibody in mouse ascitic fluid
43. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses
44. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells
45. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein
46. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis
47. Strategies for obtaining high level expression in mammalian cells
48. Polykaryocytosis induced by certain arboviruses in monolayers of BHK-21-528 cells
49. Flaviviruses can mediate fusion from without in Aedes albopictus mosquito cell cultures
50. Differences in fusogenicity and mouse neurovirulence of Japanese encephalitis viruses
51. Fusion activity of flaviviruses: Comparison of mature and immature (prM-containing) tick-borne encephalitis virions
52. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis
53. Induction of programmed cell death (apoptosis) by dengue virus in vitro and in vivo
54. Potential dengue virus-triggered apoptotic pathway in human neuroblastoma cells: Arachidonic acid, superoxide anion, and NF-KappaB are sequentially involved
55. Anti-apoptotic but not antiviral function of human bcl-2 assists establishment of Japanese encephalitis virus persistence in cultured cells
56. Evaluation of the severe combined immunodeficient (SCID) mouse as an animal model for dengue viral infection
57. Development of a novel mouse model for dengue virus infection
58. Study of dengue virus infection in SCID mice engrafted with human K562 cells
59. New mouse model for dengue virus vaccine testing
60. Manifestation of thrombocytopenia in dengue type 2 virus-infected mice
61. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes
62. Research on dengue during World War II
63. Immunological parameters of togavirus disease syndromes